Erratum: A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis

Alejandro Arroliga, Robert Balk, Chad Cannon, Nathan Dean, Phillip Dellinger, Paula Dennen, Juan Figueroa, Eugene Fletcher, Kalpalatha K. Guntupalli, David T. Huang, Mitchell Levy, Takkin Lo, Imrana Malik, Benjamin Margolis, George Matuschak, Laura Moore, Gregory J. Moran, Eugene Moretti, Peter Morris, Edward A PanacekEmanual Rivers, Greg Schmidt, Michael G. Seneff, Jay Steingrub, Robert Taylor

Research output: Contribution to journalArticle

Original languageEnglish (US)
JournalCritical Care Medicine
Volume42
Issue number5
DOIs
StatePublished - 2014

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Arroliga, A., Balk, R., Cannon, C., Dean, N., Dellinger, P., Dennen, P., Figueroa, J., Fletcher, E., Guntupalli, K. K., Huang, D. T., Levy, M., Lo, T., Malik, I., Margolis, B., Matuschak, G., Moore, L., Moran, G. J., Moretti, E., Morris, P., ... Taylor, R. (2014). Erratum: A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Critical Care Medicine, 42(5). https://doi.org/10.1097/CCM.0000000000000348